A characteristic feature of AD progression is a reduction in amyloid-β (Aβ) protein (that is, low CSF Aβ42 level) and an increase of neuronal degeneration biomarkers (that is, increase of CSF total tau and phosphorylated tau (p-tau181) levels) in CSF of subjects with AD [5]. This evidence concerns the gene MAPT and Alzheimer disease.